Medical Advocates
Pegylated Interferon alfa-2b (PEG-INTRON)
    HCV Adverse Events

General Reports
Autoimmune Hepatitis
Blood Disorders
Cutaneous Disorders
Depression
 Eye Disorders
 Hearing Loss
 Renal Disorders
 Thyroid Dysfunction
 Thrombosis
 Thrombotic Thrombocytopenic Purpura 		 
Peg Inf Alfa-2b Journal Main Page Main New/Newsworthy Home Page

Last Update:  January 26, 2015

 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
 
 
Peginterferon alpha-2b and acute allograft failure in a heart transplant recipient.
Wang BY, Chang HH, Chen IM, et al
Ann Thorac Surg. 2010 May;89(5):1645-7.
 Abstract

Relationship between Patient Profile and Feverishness Developed during Interferon-Ribavirin Combination Therapy of Chronic Hepatitis C Patients.
 Motegi E, Uesawa Y, Dai Y, Ishii K, Mohri K.
Yakugaku Zasshi. 2008 Dec;128(12):1803-10.
 Abstract
 
Toxicity of the treatment of chronic hepatitis C with peginterferon a (2a or 2b) plus ribavirin in patients not previously treated
 Márquez Peiró JF, Valero Alcocer VE, Morales Suárez-Varela M, et al
Med Clin (Barc). 2007 Nov 3;129(16):612-4.
Abstract

Serious side-effects of interferon alfa and ribavirin combination
 Stransky J, Skrivankova J.
 Vnitr Lek 2002 Jan;48(1):56-9
 Abstract
Autoimmune Hepatitis
 

     Peg Interferon alfa-2b/Ribavirin
 
  High incidence of allograft dysfunction in liver transplant patients treated with Peg-Interferon alfa-2band Ribavirin for hepatitis C recurrence: possible de novo
autoimmune hepatitis?
 Berardi S, Lodato F, Gramenzi A, D'Errico A, et al
 Gut. 2006 Jun 23;
 Abstract

Blood Disorders
 

     Peg Interferon alfa-2b/Ribavirin
 
  Investigation of hyperuricemia during pegylated-interferon-alpha2b plus ribavirin combination therapy in patients with chronic hepatitis C.
 Yamashita N, Enjoji M, Kotoh K, et al
J Dig Dis. 2008 Feb;9(1):27-31.
 Abstract

Cutaneous Disorders
 
 
FULL TEXT PDF ARTICLE
 Extensive psoriasis induced by pegylated interferon: a case report
Citro V, Fristachi R, Tarantino G 
Journal of Medical Case Reports 2007, 1:86 (17 Sep 2007)
 Paper

Necrotizing cutaneous lesions complicating treatment with pegylated-interferon alfa in an HIV-infected patient.
 Bessis D, Charron A, Rouzier-Panis R, et al.
Eur J Dermatol 2002 Jan-Feb;12(1):99-102
 Abstract
Depression
 
 
The Effect of Pegylated Interferon-{alpha}2b and Ribavirin on Posttraumatic Stress Disorder Symptoms.
 Dieperink E, Leskela J, Dieperink ME, et al  
Psychosomatics. 2008 May-Jun;49(3):225-9.
 Abstract
 
An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha-2b and ribavirin treatment.
Robaeys G, De Bie J, Van Ranst M, Buntinx F.
World J Gastroenterol. 2007 Apr 28;13(16):2379-80.
 Abstract

Serotonin-1A Receptor Gene HTR1A Variation Predicts Interferon-Induced Depression in Chronic Hepatitis C.
 Kraus MR, Al-Taie O, Schafer A, et al 
Gastroenterology. 2007 Apr;132(4):1279-86.
Abstract
Eye Disorders
 
 
UK prospective study of change in visual function in patients treated with Peginterferon alpha for hepatitis C.
 Malik NN, Sheth HG, Ackerman N, et al
Br J Ophthalmol. 2007 Oct 25;
Abstract

Bilateral AION after the Combined Therapy of Hepatitis C with PEG-Interferon alpha2B and Ribavirin
 Kirchhoff A, Kirchhoff U, Lafrenz M, Guthoff R.et al 
Klin Monatsbl Augenheilkd. 2004 Sep;221(9):791-3.
Abstract
Mental Health Disorders
 
  Major depressive episode with psychotic features induced by pegylated interferon-alpha-2b and ribavirin treatment.
Sockalingam S, Balderson K.
Int Clin Psychopharmacol. 2005 Sep;20(5):289-290.
 Abstract
Hearing Loss
 
          Journal Papers, Abstracts, and Commentaries
 
 
FULL-TEXT ARTICLE
Acute sensorineural hearing loss associated with peginterferon and ribavirin combination therapyduring hepatitis C treatment: Outcome after resumption of therapy.
 Wong VK, Cheong-Lee C, Ford JA, Yoshida EM. 
World J Gastroenterol. 2005 Sep 14;11(34):5392-3.
Paper
 
Sudden hearing loss in patients with chronic hepatitis C treated with pegylated interferon/ribavirin.
 Formann E, Stauber R, Denk DM, et al.
 Am J Gastroenterol. 2004 May;99(5):873-7
 Abstract
Renal Disorders
 
  De novo nephrotic syndrome following pegylated interferon alfa 2b/ribavirin therapy for chronic hepatitis C infection.
Tovar JL, Buti M, Segarra A, Majó J, Esteban R.
Int Urol Nephrol. 2007 Nov 7
 Abstract
Thyroid Dysfunction
 
  Thyroid dysfunction in patients with chronic hepatitis C receiving a combined therapy of interferon and ribavirin: Incidence, associated factors and prognosis.
 Kee KM, Lee CM, Wang , et al 
 J Gastroenterol Hepatol. 2006 Jan;21(1):319-326.
Abstract
Vascular Disorders
 
 
Cryoglobulinemia-Related Vasculitis During Effective Anti-HCV Treatment with PEG-Interferon alfa-2b.
 De Blasi T, Aguilar Marucco D, Cariti G, et al  
Infection. 2007 Oct 25;
 Abstract

A case of deep venous thrombosis associated with pegylated interferon alpha2b plus ribavirin treatment of chronic hepatitis C.
 Okuse C, Adachi K, Katakura Y, Matsunaga K, et al
J Gastroenterol. 2006 Dec;41(12):1231-6.
Abstract
Thrombotic Thrombocytopenic Purpura
 
  Thrombotic thrombocytopenic purpura with fatal outcome in a patient with chronic hepatitis C treated with pegylated interferon-a/2b.
 Deutsch M, Manesis EK, Hadziyannis E, et al 
Scand J Gastroenterol. 2007 Mar;42(3):408-9.
Abstract

Peg Inf Alfa-2b Journal Main Page Main New/Newsworthy Home Page

Peginterferon alfa-2b HCV Indications